Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab for Late ABMR in Kidney Transplant
NCT07081126Recruiting
- Sponsor
- University Hospital Martin
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of daratumumab in antibody mediated rejection (AMR) (2 arms), sponsored by University Hospital Martin. Primary endpoint: Treatment Success Rate at 7 months. Started Jul 2025; status: recruiting.
02
Drugs
daratumumab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT07081126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07081126.